About this event
CEO Q&A: Our FDA Breakthrough Milestone Is One of Many
Join Andrew Simpson, CEO of HeartSciences (Nasdaq: HSCS), for a live Q&A on Wednesday, August 20th at 2 PM ET (11 AM PT).
Andrew will walk through HeartSciences’ recent momentum, including:
Don’t miss this opportunity to hear what’s ahead and why this is could be a defining moment in the Company’s development.
Disclaimer: HeartSciences is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. Before making any investment, you are urged to read the Final Offering Circular carefully for a more complete understanding of the issuer and the offering. There is no guarantee of return, and you should only invest money that you can afford to lose. Use proper risk management when considering this investment.
The securities offered by HeartSciences are highly speculative. Investing in these securities involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Investors must understand that such investment could be illiquid for an indefinite period of time. There is no existing public trading market for the Series D Preferred Stock. HeartSciences does not intend to apply for listing of the Series D Preferred Stock or the common stock purchase warrants on a national securities exchange or quoted on an over the counter market.
For additional information on HeartSciences, the offering and any other related topics, please review the Form 1-A offering circular that can be found by searching for HeartSciences under Filings/Company filings search on www.sec.gov. Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
Hosted by
